LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Reduced Monocytic Human Leukocyte Antigen-DR Expression Indicates Immunosuppression in Critically Ill COVID-19 Patients.

    Spinetti, Thibaud / Hirzel, Cedric / Fux, Michaela / Walti, Laura N / Schober, Patrick / Stueber, Frank / Luedi, Markus M / Schefold, Joerg C

    Anesthesia and analgesia

    2020  Volume 131, Issue 4, Page(s) 993–999

    Abstract: ... to noncritically ill hospitalized COVID-19 patients, ICU patients with severe COVID-19 disease showed reduced mHLA-DR ... noncritically ill patients (n = 7), 89% (8 of 9) critically ill patients with COVID-19-induced acute respiratory ... of the surface expression of monocytic human leukocyte antigen-DR (mHLA-DR ...

    Abstract Background: The cellular immune system is of pivotal importance with regard to the response to severe infections. Monocytes/macrophages are considered key immune cells in infections and downregulation of the surface expression of monocytic human leukocyte antigen-DR (mHLA-DR) within the major histocompatibility complex class II reflects a state of immunosuppression, also referred to as injury-associated immunosuppression. As the role of immunosuppression in coronavirus disease 2019 (COVID-19) is currently unclear, we seek to explore the level of mHLA-DR expression in COVID-19 patients.
    Methods: In a preliminary prospective monocentric observational study, 16 COVID-19-positive patients (75% male, median age: 68 [interquartile range 59-75]) requiring hospitalization were included. The median Acute Physiology and Chronic Health Evaluation-II (APACHE-II) score in 9 intensive care unit (ICU) patients with acute respiratory failure was 30 (interquartile range 25-32). Standardized quantitative assessment of HLA-DR on monocytes (cluster of differentiation 14+ cells) was performed using calibrated flow cytometry at baseline (ICU/hospital admission) and at days 3 and 5 after ICU admission. Baseline data were compared to hospitalized noncritically ill COVID-19 patients.
    Results: While normal mHLA-DR expression was observed in all hospitalized noncritically ill patients (n = 7), 89% (8 of 9) critically ill patients with COVID-19-induced acute respiratory failure showed signs of downregulation of mHLA-DR at ICU admission. mHLA-DR expression at admission was significantly lower in critically ill patients (median, [quartiles]: 9280 antibodies/cell [6114, 16,567]) as compared to the noncritically ill patients (30,900 antibodies/cell [26,777, 52,251]), with a median difference of 21,508 antibodies/cell (95% confidence interval [CI], 14,118-42,971), P = .002. Reduced mHLA-DR expression was observed to persist until day 5 after ICU admission.
    Conclusions: When compared to noncritically ill hospitalized COVID-19 patients, ICU patients with severe COVID-19 disease showed reduced mHLA-DR expression on circulating CD14+ monocytes at ICU admission, indicating a dysfunctional immune response. This immunosuppressive (monocytic) phenotype remained unchanged over the ensuing days after ICU admission. Strategies aiming for immunomodulation in this population of critically ill patients should be guided by an immune-monitoring program in an effort to determine who might benefit best from a given immunological intervention.
    MeSH term(s) APACHE ; Aged ; Antibodies/analysis ; Antibodies/immunology ; COVID-19 ; Coronavirus Infections/immunology ; Coronavirus Infections/therapy ; Critical Care ; Critical Illness ; Down-Regulation/immunology ; Female ; HLA-DR Antigens/biosynthesis ; HLA-DR Antigens/immunology ; Humans ; Immune Tolerance/immunology ; Immunotherapy ; Lipopolysaccharide Receptors/immunology ; Male ; Middle Aged ; Monocytes/immunology ; Pandemics ; Pneumonia, Viral/immunology ; Pneumonia, Viral/therapy ; Prospective Studies ; Respiratory Insufficiency/immunology ; Respiratory Insufficiency/physiopathology
    Chemical Substances Antibodies ; HLA-DR Antigens ; Lipopolysaccharide Receptors
    Keywords covid19
    Language English
    Publishing date 2020-12-31
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80032-6
    ISSN 1526-7598 ; 0003-2999
    ISSN (online) 1526-7598
    ISSN 0003-2999
    DOI 10.1213/ANE.0000000000005044
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Reduced Monocytic Human Leukocyte Antigen-DR Expression Indicates Immunosuppression in Critically Ill COVID-19 Patients

    Spinetti, Thibaud / Hirzel, Cedric / Fux, Michaela / Walti, Laura N. / Schober, Patrick / Stueber, Frank / Luedi, Markus M. / Schefold, Joerg C.

    Anesthesia & Analgesia

    2020  Volume 131, Issue 4, Page(s) 993–999

    Keywords Anesthesiology and Pain Medicine ; covid19
    Language English
    Publisher Ovid Technologies (Wolters Kluwer Health)
    Publishing country us
    Document type Article ; Online
    ZDB-ID 80032-6
    ISSN 1526-7598 ; 0003-2999
    ISSN (online) 1526-7598
    ISSN 0003-2999
    DOI 10.1213/ane.0000000000005044
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article: Reduced Monocytic Human Leukocyte Antigen-DR Expression Indicates Immunosuppression in Critically Ill COVID-19 Patients

    Spinetti, Thibaud / Hirzel, Cedric / Fux, Michaela / Walti, Laura N / Schober, Patrick / Stueber, Frank / Luedi, Markus M / Schefold, Joerg C

    Anesth Analg

    Abstract: ... to noncritically ill hospitalized COVID-19 patients, ICU patients with severe COVID-19 disease showed reduced mHLA-DR ... noncritically ill patients (n = 7), 89% (8 of 9) critically ill patients with COVID-19-induced acute respiratory ... of the surface expression of monocytic human leukocyte antigen-DR (mHLA-DR ...

    Abstract BACKGROUND: The cellular immune system is of pivotal importance with regard to the response to severe infections. Monocytes/macrophages are considered key immune cells in infections and downregulation of the surface expression of monocytic human leukocyte antigen-DR (mHLA-DR) within the major histocompatibility complex class II reflects a state of immunosuppression, also referred to as injury-associated immunosuppression. As the role of immunosuppression in coronavirus disease 2019 (COVID-19) is currently unclear, we seek to explore the level of mHLA-DR expression in COVID-19 patients. METHODS: In a preliminary prospective monocentric observational study, 16 COVID-19-positive patients (75% male, median age: 68 [interquartile range 59-75]) requiring hospitalization were included. The median Acute Physiology and Chronic Health Evaluation-II (APACHE-II) score in 9 intensive care unit (ICU) patients with acute respiratory failure was 30 (interquartile range 25-32). Standardized quantitative assessment of HLA-DR on monocytes (cluster of differentiation 14+ cells) was performed using calibrated flow cytometry at baseline (ICU/hospital admission) and at days 3 and 5 after ICU admission. Baseline data were compared to hospitalized noncritically ill COVID-19 patients. RESULTS: While normal mHLA-DR expression was observed in all hospitalized noncritically ill patients (n = 7), 89% (8 of 9) critically ill patients with COVID-19-induced acute respiratory failure showed signs of downregulation of mHLA-DR at ICU admission. mHLA-DR expression at admission was significantly lower in critically ill patients (median, [quartiles]: 9280 antibodies/cell [6114, 16,567]) as compared to the noncritically ill patients (30,900 antibodies/cell [26,777, 52,251]), with a median difference of 21,508 antibodies/cell (95% confidence interval [CI], 14,118-42,971), P = .002. Reduced mHLA-DR expression was observed to persist until day 5 after ICU admission. CONCLUSIONS: When compared to noncritically ill hospitalized COVID-19 patients, ICU patients with severe COVID-19 disease showed reduced mHLA-DR expression on circulating CD14+ monocytes at ICU admission, indicating a dysfunctional immune response. This immunosuppressive (monocytic) phenotype remained unchanged over the ensuing days after ICU admission. Strategies aiming for immunomodulation in this population of critically ill patients should be guided by an immune-monitoring program in an effort to determine who might benefit best from a given immunological intervention.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #760675
    Database COVID19

    Kategorien

  4. Article ; Online: Reduced monocytic HLA-DR expression indicates immunosuppression in critically ill COVID-19 patients.

    Spinetti, Thibaud / Hirzel, Cedric / Fux, Michaela / Walti, Laura N. / Schober, Patrick / Stueber, Frank / Luedi, Markus M. / Schefold, Joerg C.

    Spinetti, Thibaud; Hirzel, Cedric; Fux, Michaela; Walti, Laura N.; Schober, Patrick; Stueber, Frank; Luedi, Markus M.; Schefold, Joerg C. (2020). Reduced monocytic HLA-DR expression indicates immunosuppression in critically ill COVID-19 patients. Anesthesia and analgesia, 131(4), pp. 993-999. International Anesthesia Research Society 10.1213/ANE.0000000000005044

    2020  

    Abstract: ... patients, ICU patients with severe COVID-19 disease showed reduced mHLA-DR expression on circulating CD14+ ... admission. Baseline data was compared to hospitalized non-critically ill COVID-19 patients. RESULTS ... critically ill patients with COVID-19- induced acute respiratory failure showed signs of downregulation of mHLA ...

    Abstract BACKGROUND The cellular immune system is of pivotal importance with regard to the response to severe infections. Monocytes / macrophages are considered key immune cells in infections and downregulation of the surface expression of monocytic human leukocyte antigen-DR (mHLA-DR) expression within the major histocompatibility complex class II reflects a state of immunosuppression, also referred to as injury-associated immunosuppression. As the role of immunosuppression in coronavirus disease 2019 (COVID-19) disease is currently unclear, we seek to explore the level of mHLA-DR expression in COVID-19 patients. METHODS In a preliminary prospective monocentric observational study, 16 COVID-19 positive patients (75% male, median age: 68 [interquartile range 59-75], APACHE-II score in 9 ICU patients: 30 [interquartile range 25-32] with acute respiratory failure were included. Standardized quantitative assessment of mHLA-DR on CD14+ cells was performed using calibrated flow cytometry at baseline (ICU admission), and at days 3 and 5 after ICU admission. Baseline data was compared to hospitalized non-critically ill COVID-19 patients. RESULTS While normal mHLA-DR expression was observed in all hospitalized non-critically ill patients (n=7), 89% (8/9) critically ill patients with COVID-19- induced acute respiratory failure showed signs of downregulation of mHLA-DR at ICU admission. Monocytic HLA-DR expression at admission was significantly lower in critically ill patients (median, [quartiles]: 9280 antibodies/cell [6114, 16567]) as compared to the non-critically ill patients (30900 antibodies/cell [26777, 52251]), with a median difference of 21508 antibodies/cell (95% CI: 14118 to 42971), P=0.002. Reduced monocytic HLA-DR expression was observed to persist until day 5 after ICU admission. CONCLUSIONS When compared to non-critically ill hospitalized COVID-19 patients, ICU patients with severe COVID-19 disease showed reduced mHLA-DR expression on circulating CD14+ monocytes at ICU admission, indicating a dysfunctional immune response. This immunosuppressive (monocytic) phenotype remained unchanged over the ensuing days after ICU admission. Strategies aiming for immunomodulation in this population of critically ill patients should be guided by an immune-monitoring program in an effort to determine who might benefit best from a given immunological intervention.
    Keywords 610 Medicine & health ; covid19
    Language English
    Publishing date 2020-06-04
    Publisher International Anesthesia Research Society
    Publishing country ch
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top